



8. Rogers JD, Sanders P, Piorkowski C, Sohail MR, Anand R et al. (2017) In-office insertion of a miniaturized insertable cardiac monitor: Results from the Reveal LINQ In-Office 2 randomized study. *Heart Rhythm* 14: 218-224.
9. Camm AJ (2009) The rely study: Randomized evaluation of long-term anticoagulant therapy: Dabigatran vs. warfarin. *Eur Heart J* 30: 2554-2555.
10. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, et al. (2012) J-ROCKET AF study investigators. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation-The J-ROCKET AF study. *Circ J* 76: 2104-2111.
11. Guimarães PO, Pokorney SD, Lopes RD, Wojdyla DM, Gersh BJ, et al. (2019) Efficacy and safety of apixaban vs. warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial. *Clin Cardiol* 42: 568-571.
12. Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, et al. (2014) Atrial fibrillation in patients with cryptogenic stroke. *N Engl J Med* 370: 2467-2477.
13. Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, et al. (2014) CRYSTAL AF Investigators. Cryptogenic stroke and underlying atrial fibrillation. *N Engl J Med* 370: 2478-2486.
14. Tsivgoulis G, Katsanos AH, Grory BM, Köhrmann M, Ricci BA, et al. (2019) Prolonged cardiac rhythm monitoring and secondary stroke prevention in patients with cryptogenic cerebral ischemia. *Stroke* 50: 2175-2180.
15. Steinhaus DA, Zimetbaum P, Passman R, Peter Leong-Sit 3, Matthew R Reynolds (2016) Cost effectiveness of implantable cardiac monitor-guided intermittent anticoagulation for atrial fibrillation: An Analysis of the REACT.COM Pilot Study. *Cardiovasc Electrophysiol* 27: 1304-1311.